Amgen Inc. Other Nonrecurring (Income) Expense
Amgen Inc. (AMGN) reported Other Nonrecurring (Income) Expense of $116.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherNonrecurringIncomeExpense · last filed 2026-08-05
- Amgen Inc. other nonrecurring (income) expense for the quarter ending 2026-06-30 was $116.00M, a 50.65% increase year-over-year.
- Amgen Inc. other nonrecurring (income) expense for the quarter ending 2026-03-31 was -$113.00M, a 113.61% decline year-over-year.
- Amgen Inc. other nonrecurring (income) expense for the quarter ending 2025-06-30 was $77.00M.
- Amgen Inc. other nonrecurring (income) expense for the quarter ending 2025-03-31 was $830.00M.
| Period end | Other Nonrecurring (Income) Expense 3 month | Other Nonrecurring (Income) Expense 6 month |
|---|---|---|
| 2026-06-30 | $116.00M 10-Q · filed 2026-08-05 | $3.00M 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$113.00M 10-Q · filed 2026-05-01 | |
| 2025-06-30 | $77.00M 10-Q · filed 2026-08-05 | $907.00M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $830.00M 10-Q · filed 2026-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |